What is AMGN (Amgen) average time for price targets to be met?

On average it took 550 days for the stock forecasts to be reached, with an average price target met ratio of 89.69%.

Which analyst has the most public recommendations on AMGN (Amgen)?

Emily Field works at BARCLAYS and has 3 price targets and 2 ratings on AMGN

Which analyst is the currently most bullish on AMGN (Amgen)?

David Amsellem with the highest potential upside of $68.67

Which analyst is the currently most reserved on AMGN (Amgen)?

Joshua Schimmer with the lowest potential downside of -$245.34

Amgen (AMGN) - Analyst Price Targets & Ratings History

AMGN - Amgen - Stock Forecast

Healthcare - Sector

Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

AMGN is currently covered by 21 analysts with an average price target of $384.46. This is a potential downside of $54.8 (-12.48%) from yesterday's end of day stock price of $439.26.

Amgen's activity chart (see below) currently has 716 price targets and 573 ratings on display. The stock rating distribution of AMGN is 62.82% HOLD, 35.9% BUY and 1.28% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 89.69% with an average time for these price targets to be met of 549.58 days.

Highest price target for AMGN is $500, Lowest price target is $285, average price target is $384.46.

Most recent stock forecast was given by EMILY FIELD from BARCLAYS.

What is Amgen?

Amgen is a biotechnology company that specializes in developing, manufacturing, and delivering human therapeutics.

The company’s research focuses on six main therapeutic areas, which include inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Products

Amgen produces drugs such as Enbrel, Neulasta, Prolia, Xgeva, Aranesp, KYPROLIS, and Repatha, which treat anemia, cardiovascular disease, multiple myeloma, osteoporosis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.

Enbrel
- Treats inflammatory conditions such as plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. A healthcare provider or the patient injects Enbrel to inhibit tumor necrosis factor (TNF).
Neulasta
- This product reduces the risk of infection in cancer patients undergoing chemotherapy, by stimulating the bone marrow to produce more white blood cells. It is administered by injection, usually 24 hours after chemotherapy.
Prolia
- Treats postmenopausal women with osteoporosis by inhibiting RANKL, a protein involved in bone tissue breakdown. It is given by injection every six months. Prolia can increase bone density and reduce fractures.

History

Amgen was founded in 1980 and is headquartered in Thousand Oaks, California.